X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (136) 136
hiv infections - drug therapy (114) 114
female (108) 108
male (108) 108
adult (105) 105
index medicus (101) 101
infectious diseases (101) 101
middle aged (79) 79
immunology (63) 63
anti-hiv agents - therapeutic use (58) 58
treatment outcome (58) 58
hiv infections - virology (57) 57
hiv (54) 54
drug therapy (51) 51
tenofovir (50) 50
antiretroviral therapy (48) 48
drug therapy, combination (48) 48
viral load (45) 45
anti-hiv agents - administration & dosage (44) 44
adenine - analogs & derivatives (41) 41
human immunodeficiency virus--hiv (41) 41
rna, viral - blood (41) 41
anti-hiv agents - adverse effects (40) 40
aged (39) 39
aids/hiv (39) 39
double-blind method (39) 39
safety (39) 39
hiv infection (38) 38
virology (38) 38
antiretroviral drugs (35) 35
hiv-1 - drug effects (35) 35
cd4 lymphocyte count (34) 34
emtricitabine (34) 34
young adult (33) 33
dosage and administration (32) 32
antiviral agents (31) 31
pharmacology & pharmacy (31) 31
research (31) 31
hiv-1 (30) 30
lamivudine (30) 30
efficacy (29) 29
therapy (29) 29
adenine - therapeutic use (27) 27
drug administration schedule (26) 26
adenine - administration & dosage (25) 25
clinical trials (25) 25
efavirenz (25) 25
adolescent (24) 24
double-blind (24) 24
hiv infections - immunology (24) 24
hiv-1 - genetics (24) 24
health aspects (23) 23
deoxycytidine - analogs & derivatives (22) 22
drug combinations (22) 22
lamivudine - therapeutic use (22) 22
organophosphonates - administration & dosage (21) 21
ritonavir (21) 21
abridged index medicus (20) 20
aids (20) 20
lamivudine - administration & dosage (20) 20
microbiology (20) 20
protease inhibitors (20) 20
abacavir (19) 19
drug resistance, viral (19) 19
hiv-1 - isolation & purification (19) 19
ritonavir - therapeutic use (19) 19
deoxycytidine - administration & dosage (18) 18
dideoxynucleosides - therapeutic use (18) 18
hiv/aids (18) 18
medicine, general & internal (18) 18
pharmacokinetics (18) 18
ritonavir - administration & dosage (18) 18
organophosphonates - therapeutic use (17) 17
adults (16) 16
atazanavir sulfate (16) 16
care and treatment (16) 16
reverse transcriptase inhibitors - therapeutic use (16) 16
adenine - adverse effects (15) 15
cobicistat (15) 15
comparative analysis (15) 15
dideoxynucleosides - administration & dosage (15) 15
hiv infections - blood (15) 15
raltegravir (15) 15
reverse transcriptase inhibitors - administration & dosage (15) 15
ribonucleic acid--rna (15) 15
antiretroviral therapy, highly active - methods (14) 14
combination (14) 14
lamivudine - adverse effects (14) 14
rna (14) 14
viruses (14) 14
deoxycytidine - therapeutic use (13) 13
anti-hiv agents - pharmacology (12) 12
anti-retroviral agents - therapeutic use (12) 12
carbamates - administration & dosage (12) 12
drug resistance (12) 12
hiv protease inhibitors - administration & dosage (12) 12
infection (12) 12
infections (12) 12
organophosphonates - adverse effects (12) 12
raltegravir potassium (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1087 - 1097
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 43 - 52
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 396 - 407
Journal Article